Drug
Nbip 01435
Nbip 01435: highest development phase Phase 2, developed by Neurocrine Biosciences. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Neurocrine Biosciences
Trials
| Drug | Phase | Indication |
|---|---|---|
| NBIP-01435 NCT07850739 | Phase 2 | Congenital Adrenal Hyperplasia |
Latest
No recent events.
Follow Nbip 01435 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.